✦ LIBER ✦

368 POSTER Discovery and characterization of a new potent orally available Cdc7 inhibitor with anti-tumor activity

✍ Scribed by A. Montagnoli; E. Vanotti; S. Rainoldi; V. Marchesi; A. Ciavolella; V. Croci; V. Patton; C. Albanese; C. Santocanale; J. Moll

Book ID: 119599524
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)72302-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

102 Identification and preclinical chara

102 Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer

✍ E. Ardini; A. Lombardi Borgia; C. De Ponti; N. Amboldi; D. Ballinari; M.B. Sacca 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Identification and characterization of N

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

✍ Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; B 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 833 KB

156 POSTER BIIB021, a fully synthetic or

156 POSTER BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows potent anti-tumor activity as a single agent and in combination with standard of care therapies in preclinical tumor models

✍ K. Lundgren; N. Timple; G. Ibanez; C. Yang; L. Neely; A. Kamal; K. Hong; H. Zhan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB